Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Kratom Industry Argues FDA Wants To Label All Products As Adverse Events Without Evidence

Aug 26 2024

• By Malcolm Spicer

Related Content

US Kratom Industry Chafes At FDA’s Short Leash On Science Showing Botanical’s Safety, Benefits

Aug 12 2021

Latest US FDA Spending On Kratom Research Goes To Testing Human Abuse Potential

Jan 17 2024

US HHS Pulled Recommendation To Make Kratom A Controlled Substance, But Kept Mum On Change

Jan 29 2021

US FDA Funds Study To Learn Whether Kratom Users Have ‘Any Risk/Safety Considerations’

Aug 01 2024

Additional Topics

International United States Dietary Supplements Enforcement Safety Advertising, Marketing & Sales Business Strategies Commercial Compliance Consumer FDA Ingredients Manufacturing Policy Regulation Regulatory Retail

More from Compliance

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.